Ledger.

Co-founder and Chief Scientific Officer, Glyscend

Thomas Jozefiak

Coverage

Stories naming Thomas Jozefiak. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Series A $29m

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.

Brandon Capital portfolio Tue 3 Aug 2021 Glyscend, Inc.Brandon CapitalCentre of Research Excellence in Translating Nutritional Science to Good HealthCMAXMana CommunicationsPayPalRoyal Adelaide HospitalThiel FoundationUniversity of AdelaideBreakout LabsMedical Research Commercialisation Fund (MRCF)Santé VenturesAshish NimgaonkarDr Bob SohCaleb Hulme-MoirProfessor Chris RaynerCiara ByrneProfessor Michael HorowitzPeter ThielThomas Jozefiak

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio

Something wrong? Tell us